GSK plc Logo

GSK plc

GSK

(2.2)
Stock Price

41,62 USD

15.74% ROA

38.66% ROE

10.53x PER

Market Cap.

64.282.157.531,28 USD

158.65% DER

4.4% Yield

16.25% NPM

GSK plc Stock Analysis

GSK plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

GSK plc Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (50.35%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

4 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

5 Net Profit Growth

This company's net profit has been consistently on the rise over the past three years, indicating a strong financial performance and making it an appealing investment opportunity.

6 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (148), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

7 PBV

The stock's elevated P/BV ratio (4.36x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

8 DER

The stock is burdened with a heavy load of debt (159%), making it financially unstable and potentially risky for investors.

9 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

GSK plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

GSK plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

GSK plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

GSK plc Revenue
Year Revenue Growth
1986 1.429.000.000
1987 1.741.000.000 17.92%
1988 2.059.000.000 15.44%
1989 2.570.000.000 19.88%
1990 3.179.000.000 19.16%
1991 3.397.000.000 6.42%
1992 4.096.000.000 17.07%
1993 4.930.000.000 16.92%
1994 5.656.000.000 12.84%
1995 10.490.000.000 46.08%
1996 8.341.000.000 -25.76%
1997 7.980.000.000 -4.52%
1998 7.983.000.000 0.04%
1999 8.490.000.000 5.97%
2000 18.079.000.000 53.04%
2001 20.534.030.280 11.96%
2002 21.212.000.000 3.2%
2003 21.441.000.000 1.07%
2004 19.986.000.000 -7.28%
2005 21.660.000.000 7.73%
2006 23.225.000.000 6.74%
2007 22.716.000.000 -2.24%
2008 24.352.000.000 6.72%
2009 28.368.000.000 14.16%
2010 28.392.000.000 0.08%
2011 27.387.000.000 -3.67%
2012 26.431.000.000 -3.62%
2013 26.505.000.000 0.28%
2014 23.006.000.000 -15.21%
2015 23.923.000.000 3.83%
2016 27.889.000.000 14.22%
2017 30.186.000.000 7.61%
2018 30.821.000.000 2.06%
2019 33.754.000.000 8.69%
2020 34.099.000.000 1.01%
2021 34.114.000.000 0.04%
2022 29.324.000.000 -16.33%
2023 32.588.000.000 10.02%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

GSK plc Research and Development Expenses
Year Research and Development Expenses Growth
1986 113.000.000
1987 149.000.000 24.16%
1988 230.000.000 35.22%
1989 323.000.000 28.79%
1990 420.000.000 23.1%
1991 475.000.000 11.58%
1992 595.000.000 20.17%
1993 739.000.000 19.49%
1994 858.000.000 13.87%
1995 1.540.000.000 44.29%
1996 1.161.000.000 -32.64%
1997 1.148.000.000 -1.13%
1998 1.163.000.000 1.29%
1999 1.269.000.000 8.35%
2000 2.526.000.000 49.76%
2001 2.560.903.830 1.36%
2002 2.900.000.000 11.69%
2003 2.791.000.000 -3.91%
2004 2.904.000.000 3.89%
2005 3.136.000.000 7.4%
2006 3.457.000.000 9.29%
2007 3.237.000.000 -6.8%
2008 3.681.000.000 12.06%
2009 4.106.000.000 10.35%
2010 4.457.000.000 7.88%
2011 4.009.000.000 -11.17%
2012 3.968.000.000 -1.03%
2013 3.923.000.000 -1.15%
2014 3.450.000.000 -13.71%
2015 3.560.000.000 3.09%
2016 3.628.000.000 1.87%
2017 4.476.000.000 18.95%
2018 3.893.000.000 -14.98%
2019 4.568.000.000 14.78%
2020 5.098.000.000 10.4%
2021 5.278.000.000 3.41%
2022 5.488.000.000 3.83%
2023 6.300.000.000 12.89%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

GSK plc General and Administrative Expenses
Year General and Administrative Expenses Growth
1986 0
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 7.467.295.500 100%
2002 8.041.000.000 7.13%
2003 7.597.000.000 -5.84%
2004 7.201.000.000 -5.5%
2005 7.250.000.000 0.68%
2006 7.254.967.740 0.07%
2007 6.823.511.000 -6.32%
2008 7.656.000.000 10.87%
2009 9.592.000.000 20.18%
2010 13.053.000.000 26.51%
2011 8.826.000.000 -47.89%
2012 8.739.000.000 -1%
2013 8.480.000.000 -3.05%
2014 8.246.000.000 -2.84%
2015 9.232.000.000 10.68%
2016 9.366.000.000 1.43%
2017 9.672.000.000 3.16%
2018 9.915.000.000 2.45%
2019 11.402.000.000 13.04%
2020 11.456.000.000 0.47%
2021 10.975.000.000 -4.38%
2022 8.372.000.000 -31.09%
2023 9.184.000.000 8.84%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

GSK plc EBITDA
Year EBITDA Growth
1986 661.000.000
1987 812.000.000 18.6%
1988 926.000.000 12.31%
1989 1.125.000.000 17.69%
1990 1.348.000.000 16.54%
1991 1.509.000.000 10.67%
1992 1.687.000.000 10.55%
1993 1.951.000.000 13.53%
1994 2.157.000.000 9.55%
1995 4.445.000.000 51.47%
1996 3.645.000.000 -21.95%
1997 3.361.000.000 -8.45%
1998 3.202.000.000 -4.97%
1999 3.383.000.000 5.35%
2000 5.800.000.000 41.67%
2001 6.711.618.960 13.58%
2002 7.567.000.000 11.3%
2003 7.535.000.000 -0.42%
2004 7.219.000.000 -4.38%
2005 8.286.000.000 12.88%
2006 9.120.000.000 9.14%
2007 9.025.000.000 -1.05%
2008 8.684.000.000 -3.93%
2009 9.766.000.000 11.08%
2010 5.970.000.000 -63.58%
2011 9.589.000.000 37.74%
2012 8.585.000.000 -11.69%
2013 8.547.000.000 -0.44%
2014 5.721.000.000 -49.4%
2015 12.302.000.000 53.5%
2016 4.536.000.000 -171.21%
2017 7.146.000.000 36.52%
2018 7.358.000.000 2.88%
2019 10.129.000.000 27.36%
2020 8.484.000.000 -19.39%
2021 8.786.000.000 3.44%
2022 8.805.000.000 0.22%
2023 10.208.000.000 13.74%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

GSK plc Gross Profit
Year Gross Profit Growth
1986 1.429.000.000
1987 1.741.000.000 17.92%
1988 2.059.000.000 15.44%
1989 2.570.000.000 19.88%
1990 3.179.000.000 19.16%
1991 3.397.000.000 6.42%
1992 4.096.000.000 17.07%
1993 4.930.000.000 16.92%
1994 5.656.000.000 12.84%
1995 10.490.000.000 46.08%
1996 8.341.000.000 -25.76%
1997 7.980.000.000 -4.52%
1998 6.438.000.000 -23.95%
1999 4.156.000.000 -54.91%
2000 14.117.000.000 70.56%
2001 16.094.258.550 12.29%
2002 16.603.000.000 3.06%
2003 16.897.000.000 1.74%
2004 15.626.000.000 -8.13%
2005 16.896.000.000 7.52%
2006 18.215.000.000 7.24%
2007 17.510.000.000 -4.03%
2008 17.937.000.000 2.38%
2009 20.988.000.000 14.54%
2010 20.800.000.000 -0.9%
2011 20.055.000.000 -3.71%
2012 18.537.000.000 -8.19%
2013 17.920.000.000 -3.44%
2014 15.683.000.000 -14.26%
2015 15.070.000.000 -4.07%
2016 18.599.000.000 18.97%
2017 19.844.000.000 6.27%
2018 20.580.000.000 3.58%
2019 21.891.000.000 5.99%
2020 22.395.000.000 2.25%
2021 22.511.000.000 0.52%
2022 19.770.000.000 -13.86%
2023 23.500.000.000 15.87%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

GSK plc Net Profit
Year Net Profit Growth
1986 400.000.000
1987 510.000.000 21.57%
1988 581.000.000 12.22%
1989 688.000.000 15.55%
1990 807.000.000 14.75%
1991 881.000.000 8.4%
1992 1.033.000.000 14.71%
1993 1.207.000.000 14.42%
1994 1.299.000.000 7.08%
1995 1.458.000.000 10.91%
1996 1.997.000.000 26.99%
1997 1.850.000.000 -7.95%
1998 1.836.000.000 -0.76%
1999 1.811.000.000 -1.38%
2000 4.162.000.000 56.49%
2001 3.099.787.920 -34.27%
2002 3.935.000.000 21.23%
2003 4.490.000.000 12.36%
2004 3.908.000.000 -14.89%
2005 4.689.000.000 16.66%
2006 5.389.000.000 12.99%
2007 5.214.000.000 -3.36%
2008 4.712.000.000 -10.65%
2009 5.531.000.000 14.81%
2010 1.634.000.000 -238.49%
2011 5.261.000.000 68.94%
2012 4.565.000.000 -15.25%
2013 5.436.000.000 16.02%
2014 2.756.000.000 -97.24%
2015 8.422.000.000 67.28%
2016 912.000.000 -823.46%
2017 1.532.000.000 40.47%
2018 3.623.000.000 57.71%
2019 4.645.000.000 22%
2020 5.749.000.000 19.2%
2021 4.385.000.000 -31.11%
2022 4.921.000.000 10.89%
2023 5.856.000.000 15.97%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

GSK plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1986 1
1987 1 0%
1988 1 0%
1989 1 100%
1990 1 0%
1991 1 0%
1992 1 0%
1993 1 100%
1994 1 0%
1995 1 0%
1996 1 0%
1997 1 0%
1998 1 0%
1999 1 0%
2000 2 0%
2001 1 0%
2002 2 0%
2003 2 0%
2004 2 0%
2005 2 50%
2006 2 0%
2007 2 0%
2008 222 99.1%
2009 3 -10950%
2010 1 0%
2011 3 100%
2012 2 0%
2013 3 0%
2014 1 -100%
2015 4 75%
2016 0 0%
2017 1 0%
2018 2 100%
2019 2 50%
2020 3 0%
2021 2 0%
2022 2 0%
2023 3 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

GSK plc Free Cashflow
Year Free Cashflow Growth
1991 9.000.000
1992 63.000.000 85.71%
1993 319.000.000 80.25%
1994 478.000.000 33.26%
1995 568.000.000 15.85%
1996 448.000.000 -26.79%
1997 200.000.000 -124%
1998 -65.000.000 407.69%
1999 -87.000.000 25.29%
2000 749.000.000 111.62%
2001 3.491.390.790 78.55%
2002 1.833.000.000 -90.47%
2003 3.789.840.000 51.63%
2004 4.512.000.000 16.01%
2005 4.406.000.000 -2.41%
2006 2.368.000.000 -86.06%
2007 3.652.000.000 35.16%
2008 5.242.000.000 30.33%
2009 5.968.000.000 12.16%
2010 5.162.000.000 -15.61%
2011 4.922.000.000 -4.88%
2012 2.855.000.000 -72.4%
2013 5.521.000.000 48.29%
2014 3.425.000.000 -61.2%
2015 668.000.000 -412.72%
2016 4.145.000.000 83.88%
2017 4.716.000.000 12.11%
2018 6.625.000.000 28.82%
2019 5.857.000.000 -13.11%
2020 6.202.000.000 5.56%
2021 5.021.000.000 -23.52%
2022 5.145.000.000 2.41%
2023 1.715.000.000 -200%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

GSK plc Operating Cashflow
Year Operating Cashflow Growth
1991 615.000.000
1992 657.000.000 6.39%
1993 927.000.000 29.13%
1994 1.053.000.000 11.97%
1995 1.252.000.000 15.89%
1996 849.000.000 -47.47%
1997 615.000.000 -38.05%
1998 410.000.000 -50%
1999 510.000.000 19.61%
2000 1.852.000.000 72.46%
2001 4.609.076.310 59.82%
2002 3.060.000.000 -50.62%
2003 4.851.840.000 36.93%
2004 4.767.000.000 -1.78%
2005 5.587.000.000 14.68%
2006 3.958.000.000 -41.16%
2007 5.795.000.000 31.7%
2008 7.311.000.000 20.74%
2009 7.841.000.000 6.76%
2010 6.797.000.000 -15.36%
2011 6.250.000.000 -8.75%
2012 4.375.000.000 -42.86%
2013 7.222.000.000 39.42%
2014 5.176.000.000 -39.53%
2015 2.569.000.000 -101.48%
2016 6.497.000.000 60.46%
2017 6.918.000.000 6.09%
2018 8.421.000.000 17.85%
2019 8.020.000.000 -5%
2020 8.441.000.000 4.99%
2021 7.952.000.000 -6.15%
2022 7.403.000.000 -7.42%
2023 2.212.000.000 -234.67%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

GSK plc Capital Expenditure
Year Capital Expenditure Growth
1991 606.000.000
1992 594.000.000 -2.02%
1993 608.000.000 2.3%
1994 575.000.000 -5.74%
1995 684.000.000 15.94%
1996 401.000.000 -70.57%
1997 415.000.000 3.37%
1998 475.000.000 12.63%
1999 597.000.000 20.44%
2000 1.103.000.000 45.87%
2001 1.117.685.520 1.31%
2002 1.227.000.000 8.91%
2003 1.062.000.000 -15.54%
2004 255.000.000 -316.47%
2005 1.181.000.000 78.41%
2006 1.590.000.000 25.72%
2007 2.143.000.000 25.8%
2008 2.069.000.000 -3.58%
2009 1.873.000.000 -10.46%
2010 1.635.000.000 -14.56%
2011 1.328.000.000 -23.12%
2012 1.520.000.000 12.63%
2013 1.701.000.000 10.64%
2014 1.751.000.000 2.86%
2015 1.901.000.000 7.89%
2016 2.352.000.000 19.18%
2017 2.202.000.000 -6.81%
2018 1.796.000.000 -22.61%
2019 2.163.000.000 16.97%
2020 2.239.000.000 3.39%
2021 2.931.000.000 23.61%
2022 2.258.000.000 -29.81%
2023 497.000.000 -354.33%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

GSK plc Equity
Year Equity Growth
1986 1.090.000.000
1987 1.450.000.000 24.83%
1988 1.784.000.000 18.72%
1989 2.291.000.000 22.13%
1990 2.732.000.000 16.14%
1991 3.208.000.000 14.84%
1992 3.572.000.000 10.19%
1993 4.546.000.000 21.43%
1994 5.026.000.000 9.55%
1995 91.000.000 -5423.08%
1996 1.225.000.000 92.57%
1997 1.843.000.000 33.53%
1998 2.702.000.000 31.79%
1999 3.142.000.000 14%
2000 7.711.000.000 59.25%
2001 7.533.365.580 -2.36%
2002 6.581.000.000 -14.47%
2003 5.059.000.000 -30.08%
2004 5.724.000.000 11.62%
2005 7.311.000.000 21.71%
2006 9.386.000.000 22.11%
2007 9.603.000.000 2.26%
2008 7.931.000.000 -21.08%
2009 10.005.000.000 20.73%
2010 8.887.000.000 -12.58%
2011 8.032.000.000 -10.64%
2012 5.810.000.000 -38.24%
2013 6.997.000.000 16.96%
2014 4.263.000.000 -64.13%
2015 5.114.000.000 16.64%
2016 1.124.000.000 -354.98%
2017 -68.000.000 1752.94%
2018 3.672.000.000 101.85%
2019 18.357.000.000 80%
2020 20.808.000.000 11.78%
2021 21.342.000.000 2.5%
2022 10.096.000.000 -111.39%
2023 12.619.000.000 19.99%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

GSK plc Assets
Year Assets Growth
1986 1.803.000.000
1987 2.358.000.000 23.54%
1988 2.867.000.000 17.75%
1989 3.469.000.000 17.35%
1990 4.492.000.000 22.77%
1991 5.744.000.000 21.8%
1992 5.682.000.000 -1.09%
1993 7.458.000.000 23.81%
1994 7.887.000.000 5.44%
1995 8.541.000.000 7.66%
1996 8.314.000.000 -2.73%
1997 8.437.000.000 1.46%
1998 9.346.000.000 9.73%
1999 10.427.000.000 10.37%
2000 21.590.000.000 51.7%
2001 21.965.548.680 1.71%
2002 22.327.000.000 1.62%
2003 21.200.000.000 -5.32%
2004 22.944.000.000 7.6%
2005 27.198.000.000 15.64%
2006 25.553.000.000 -6.44%
2007 31.003.000.000 17.58%
2008 39.393.000.000 21.3%
2009 42.862.000.000 8.09%
2010 42.052.000.000 -1.93%
2011 41.080.000.000 -2.37%
2012 41.475.000.000 0.95%
2013 42.086.000.000 1.45%
2014 40.651.000.000 -3.53%
2015 53.446.000.000 23.94%
2016 59.081.000.000 9.54%
2017 56.381.000.000 -4.79%
2018 58.066.000.000 2.9%
2019 79.692.000.000 27.14%
2020 80.431.000.000 0.92%
2021 79.103.000.000 -1.68%
2022 60.146.000.000 -31.52%
2023 60.862.000.000 1.18%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

GSK plc Liabilities
Year Liabilities Growth
1986 703.000.000
1987 894.000.000 21.36%
1988 1.064.000.000 15.98%
1989 1.156.000.000 7.96%
1990 1.687.000.000 31.48%
1991 2.462.000.000 31.48%
1992 2.043.000.000 -20.51%
1993 2.801.000.000 27.06%
1994 2.738.000.000 -2.3%
1995 8.320.000.000 67.09%
1996 7.047.000.000 -18.06%
1997 6.547.000.000 -7.64%
1998 6.578.000.000 0.47%
1999 7.234.000.000 9.07%
2000 12.635.000.000 42.75%
2001 13.568.454.450 6.88%
2002 14.939.000.000 9.17%
2003 15.396.000.000 2.97%
2004 17.007.000.000 9.47%
2005 19.628.000.000 13.35%
2006 15.905.000.000 -23.41%
2007 21.093.000.000 24.6%
2008 31.075.000.000 32.12%
2009 32.120.000.000 3.25%
2010 32.307.000.000 0.58%
2011 32.253.000.000 -0.17%
2012 34.728.000.000 7.13%
2013 34.274.000.000 -1.32%
2014 35.715.000.000 4.03%
2015 44.568.000.000 19.86%
2016 54.118.000.000 17.65%
2017 52.892.000.000 -2.32%
2018 54.394.000.000 2.76%
2019 61.335.000.000 11.32%
2020 59.623.000.000 -2.87%
2021 57.761.000.000 -3.22%
2022 50.050.000.000 -15.41%
2023 48.243.000.000 -3.75%

GSK plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
14.62
Net Income per Share
3
Price to Earning Ratio
10.53x
Price To Sales Ratio
2.17x
POCF Ratio
11.68
PFCF Ratio
20.31
Price to Book Ratio
4.87
EV to Sales
2.76
EV Over EBITDA
8.34
EV to Operating CashFlow
14.96
EV to FreeCashFlow
25.89
Earnings Yield
0.09
FreeCashFlow Yield
0.05
Market Cap
64,28 Bil.
Enterprise Value
81,94 Bil.
Graham Number
20.89
Graham NetNet
-19.15

Income Statement Metrics

Net Income per Share
3
Income Quality
0.84
ROE
0.5
Return On Assets
0.08
Return On Capital Employed
0.19
Net Income per EBT
0.81
EBT Per Ebit
0.84
Ebit per Revenue
0.24
Effective Tax Rate
0.12

Margins

Sales, General, & Administrative to Revenue
0.31
Research & Developement to Revenue
0.2
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.72
Operating Profit Margin
0.24
Pretax Profit Margin
0.2
Net Profit Margin
0.16

Dividends

Dividend Yield
0.04
Dividend Yield %
4.4
Payout Ratio
0.38
Dividend Per Share
1.39

Operating Metrics

Operating Cashflow per Share
2.7
Free CashFlow per Share
1.56
Capex to Operating CashFlow
-0.42
Capex to Revenue
-0.08
Capex to Depreciation
-1.38
Return on Invested Capital
0.21
Return on Tangible Assets
0.16
Days Sales Outstanding
0
Days Payables Outstanding
678.29
Days of Inventory on Hand
238.55
Receivables Turnover
0
Payables Turnover
0.54
Inventory Turnover
1.53
Capex per Share
-1.14

Balance Sheet

Cash per Share
3,30
Book Value per Share
6,48
Tangible Book Value per Share
-4.76
Shareholders Equity per Share
6.48
Interest Debt per Share
10.69
Debt to Equity
1.59
Debt to Assets
0.34
Net Debt to EBITDA
1.8
Current Ratio
0.95
Tangible Asset Value
-9,65 Bil.
Net Current Asset Value
-27,00 Bil.
Invested Capital
1.59
Working Capital
-1,15 Bil.
Intangibles to Total Assets
0.37
Average Receivables
0,00 Bil.
Average Payables
14,77 Bil.
Average Inventory
5496000000
Debt to Market Cap
0.32

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

GSK plc Dividends
Year Dividends Growth
1987 0
1988 0 0%
1989 1 0%
1990 1 0%
1991 1 100%
1992 1 0%
1993 0 0%
1994 1 100%
1995 1 0%
1996 1 0%
1997 1 0%
1998 1 0%
1999 1 0%
2000 2 50%
2001 1 0%
2002 2 100%
2003 1 0%
2004 2 0%
2005 1 0%
2006 2 0%
2007 2 50%
2008 2 0%
2009 2 -100%
2010 2 0%
2011 2 50%
2012 2 0%
2013 2 0%
2014 3 0%
2015 3 0%
2016 3 0%
2017 2 0%
2018 2 0%
2019 2 0%
2020 2 0%
2021 2 0%
2022 2 -100%
2023 1 0%

GSK plc Profile

About GSK plc

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

CEO
Ms. Emma Natasha Walmsley
Employee
70.212
Address
980 Great West Road
Brentford, TW8 9GS

GSK plc Executives & BODs

GSK plc Executives & BODs
# Name Age
1 Ms. Sally Jackson
Senior Vice President of Global Communications & Chief Executive Officer Office
70
2 Mr. Tony Wood
Chief Scientific Officer and Head of R&D
70
3 Mr. Philip C. Thomson
President of Global Affairs
70
4 Ms. Sarah Elton-Farr
Head of Investor Relations
70
5 Mr. David Simon Redfern BSc (Hons), CA
President of Corporate Development
70
6 Ms. Emma Natasha Walmsley
Chief Executive Officer & Director
70
7 Ms. Shobie Ramakrishnan
Chief Digital & Technology Officer
70
8 Mr. James Ford
Senior Vice President & Group General Counsel of Legal & Compliance
70
9 Ms. Diana Conrad
Chief People Officer
70
10 Ms. Julie Belita Brown
Chief Financial Officer & Executive Director
70

GSK plc Competitors

Novartis AG Logo
Novartis AG

NVS

(2.0)
AstraZeneca PLC Logo
AstraZeneca PLC

AZN

(3.0)
Roche Holding AG Logo
Roche Holding AG

RHHBY

(2.5)
Amgen Inc. Logo
Amgen Inc.

AMGN

(3.2)
Merck & Co., Inc. Logo
Merck & Co., Inc.

MRK

(2.2)
AbbVie Inc. Logo
AbbVie Inc.

ABBV

(2.0)
Johnson & Johnson Logo
Johnson & Johnson

JNJ

(2.8)
Sanofi Logo
Sanofi

SNY

(3.0)
Biogen Inc. Logo
Biogen Inc.

BIIB

(2.2)